ArticleBMC medical genomics2025
Novel EP300 and NSD1 variants in Chinese pediatric patients with Rubinstein-Taybi syndrome: evidence for oligogenic inheritance and phenotypic expansion.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRubinstein–Taybi syndrome (RSTS) is an autosomal-dominant neurodevelopmental disorder caused by heterozygous loss-of-function variants in CREBBP or EP300. EP300-related cases often show milder clinical features, but their full phenotypic spectrum and the potential role of oligogenic inheritance remain unclear.
methodsWe retrospectively studied seven Chinese pediatric RSTS patients. Genomic analyses included whole-exome sequencing (WES), chromosomal microarray analysis (CMA) and Sanger validation. Variants were classified by ACMG/AMP guidelines. Protein structural impacts were assessed by homology modeling. Phenotypic frequencies in our EP300-related patients were compared with published European/American cohorts using Fisher’s exact test or χ² test (p < 0.05 as significant).
resultsTwo de novo EP300 nonsense variants (c.3934 C > T, p.Arg1312Ter; c.2749 C > T, p.Gln917Ter) were identified; one of these patients also harbored a de novo NSD1 missense variant (c.5843G > A, p.Arg1948His). Five other patients carried pathogenic CREBBP variants or deletions. The patient with both EP300 and NSD1 variants exhibited additional anomalies (cryptorchidism, congenital cataracts, strabismus), suggesting synergistic epigenetic dysregulation. Homology models predicted truncation of the EP300 HAT and bromodomain regions and disruption of the NSD1 SET domain. Compared with European/American cohorts, our Chinese EP300-related patients had significantly higher rates of arched eyebrows, downslanting palpebral fissures and low-set ears (p < 0.05). To our knowledge, this is the first clinical evidence of an oligogenic inheritance pattern in RSTS involving both EP300 and NSD1.
conclusionsOur findings expand the genotypic and phenotypic landscape of RSTS in a Chinese population, delineate distinctions between EP300- and CREBBP-related cases, and underscore the value of comprehensive genomic analysis for accurate diagnosis, genetic counselling and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.